Human Genome Epidemiology Literature Finder
|
Records 1 - 17 (of 17 Records) |
| Query Trace: Schizophrenia and CYP3A4[original query] |
|---|
| Genetic susceptibility to tardive dyskinesia in chronic schizophrenia subjects: III. Lack of association of CYP3A4 and CYP2D6 gene polymorphisms. Schizophrenia research 2005 Jun 75 (1): 21-6. Tiwari Arun K, Deshpande Smita N, Rao A R, Bhatia Triptish, Lerer Bernard, Nimgaonkar Vishwajit L, Thelma B |
| Naturalistic pharmacogenetic study of treatment resistance to typical neuroleptics in European-Brazilian schizophrenics. Pharmacogenetics and genomics 2008 Jul 18 (7): 599-609. Kohlrausch FB, Gama CS, Lobato MI, Belmonte-de-Abreu P, Callegari-Jacques SM, Gesteira A, Barros F, Carracedo A, Hutz MH |
| A case-control association study between the CYP3A4 and CYP3A5 genes and schizophrenia in the Chinese Han population. Progress in neuro-psychopharmacology & biological psychiatry 2009 Jul . Du J, Xu Y, Duan S, Zhang A, Xuan J, Wang L, Yu L, Wang H, Li X, Feng G, He L, Xing Q |
| Relationship between response to risperidone, plasma concentrations of risperidone and CYP3A4 polymorphisms in schizophrenia patients. Journal of psychopharmacology (Oxford, England) 2010 Jul 24 (7): 1115-20. Du J, Zhang A, Wang L, Xuan J, Yu L, Che R, Li X, Gu N, Lin Z, Feng G, Xing Q, He |
| Lack of correlation between the steady-state plasma concentrations of aripiprazole and haloperidol in Japanese patients with schizophrenia. Therapeutic drug monitoring 2014 Dec 36 (6): 815-8. Nakamura Akifumi, Mihara Kazuo, Nemoto Kenji, Nagai Goyo, Kagawa Shoko, Suzuki Takeshi, Kondo Tsuyos |
| Fast Versus Slow Strategy of Switching Patients With Schizophrenia to Aripiprazole From Other Antipsychotics. Journal of clinical psychopharmacology 2015 Oct . Hwang Tzung-Jeng, Lo Wei-Ming, Chan Hung-Yu, Lin Ching-Feng, Hsieh Ming H, Liu Chen-Chun, Liu Chih-Min, Hwu Hai-Gwo, Kuo Ching-Hua, Chen Wei |
| Influences of CYP2D610 polymorphisms on the pharmacokinetics of iloperidone and its metabolites in Chinese patients with schizophrenia: a population pharmacokinetic analysis. Acta pharmacologica Sinica 2016 Sep . Pei Qi, Huang Lu, Huang Jie, Gu Jing-Kai, Kuang Yun, Zuo Xiao-Cong, Ding Jun-Jie, Tan Hong-Yi, Guo Cheng-Xian, Liu Shi-Kun, Yang Guo-Pi |
| Combined study of genetic and epigenetic biomarker risperidone treatment efficacy in Chinese Han schizophrenia patients. Translational psychiatry 2017 Jul 7 (7): e1170. Shi Y, Li M, Song C, Xu Q, Huo R, Shen L, Xing Q, Cui D, Li W, Zhao J, He L, Qin |
| Potential Role of Patients' CYP3A-Status in Clozapine Pharmacokinetics. The international journal of neuropsychopharmacology 2017 Mar . Tóth Katalin, Csukly Gábor, Sirok Dávid, Belic Ales, Kiss Ádám, Háfra Edit, Déri Máté, Menus Ádám, Bitter István, Monostory Katal |
| ABCB1, ABCG2 and CYP2D6 polymorphism effects on disposition and response to long-acting risperidone. Progress in neuro-psychopharmacology & biological psychiatry 2020 Jul 110042. Ganoci Lana, Trkulja Vladimir, Živkovi? Maja, Božina Tamara, Šagud Marina, Lovri? Mila, Božina Na |
| The CYP2C19*2 and CYP2C19*17 Polymorphisms Influence Responses to Clozapine for the Treatment of Schizophrenia. Neuropsychiatric disease and treatment 2020 16 427-432. Rodrigues-Silva Christielly, Semedo Agostinho Tavares, Neri Hiasmin Franciely da Silva, Vianello Rosana Pereira, Galaviz-Hernández Carlos, Sosa-Macías Martha, de Brito Rodrigo Bernini, Ghedini Paulo Cés |
| Genetic Polymorphisms Associated With the Pharmacokinetics, Pharmacodynamics and Adverse Effects of Olanzapine, Aripiprazole and Risperidone. Frontiers in pharmacology 2021 8 12 711940. Soria-Chacartegui Paula, Villapalos-García Gonzalo, Zubiaur Pablo, Abad-Santos Francisco, Koller Do |
| Variants in COMT, CYP3A5, CYP2B6, and ABCG2 Alter Quetiapine Pharmacokinetics. Pharmaceutics 2021 Sep 13 (10): . Zubiaur Pablo, Fernández-Campos Paula, Navares-Gómez Marcos, Soria-Chacartegui Paula, Villapalos-García Gonzalo, Román Manuel, Mejía-Abril Gina, Ochoa Dolores, Abad-Santos Francis |
| Pharmacokinetic interactions between clozapine and valproic acid in patients with treatment-resistant schizophrenia: Does UGT polymorphism affect these drug interactions? Chemico-biological interactions 2022 Jul 364 110042. Sangüesa Estela, Cirujeda Christine, Concha Julia, Padilla Pedro Pablo, García Cristina Belén, Ribate María Pil |
| Antipsychotic drug-aripiprazole against schizophrenia, its therapeutic and metabolic effects associated with gene polymorphisms. Pharmacological reports : PR 2022 12 75 (1): 19-31. Stelmach Adriana, Guzek Katarzyna, Ro?nowska Alicja, Najbar Irena, Sadakierska-Chudy An |
| The potential influence of estrogen-containing oral contraception on clozapine metabolism in a patient with known pharmacogenomic status. The mental health clinician 2024 6 14 (3): 220-223. Alyssa K Kuhn, Meina L Determan, Jessica A Wright, Eric Matey, Jonathan G Leu |
| Coadministration of Cariprazine with a Moderate CYP3A4 Inhibitor in Patients with Schizophrenia: Implications for Dose Adjustment and Safety Monitoring. Clinical pharmacokinetics 2024 10 . Máté Szabó, Zoltán Hujber, Judit Harsányi, Balázs Szatmári, Zsófia B Dombi, Gabriella Magyar, Zsuzsanna Heged?s, Piroska Ratskó, Gabriella Pásztor Mészáros, Ágota Barabás |
- Page last reviewed:Feb 1, 2024
- Content source: